U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07551531) titled 'GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial' on April 15.
Brief Summary: The GALACTIC Registry study purpose is to validate the Combination Model-score (CM-score) for increased accuracy in the percentage of the positive predictive value (PPV) of allograft rejection results for the GraftAssure (GraftAssureCore and GraftAssureDx) assay. This will also be correlated with the biopsy yield and treatment decisions. The GraftAssure assay is a diagnostic test intended for the quantitative measurement of dd-cfDNA in plasma from kidney transplant recipients. The test is minimally invasive, and is intended to be ...